Stock Events

Stock Events

Search...

Abeona Therapeutics

$4.98

61

-$0.02-0.4% Friday 19:55

Statistics

Day High

-

Day Low

4.88

52W High

9.01

52W Low

3.05

Volume

128,778

Avg. Volume

351,319

Mkt Cap

215.71M

P/E Ratio

0

Dividend Yield

-

Dividend

-

Upcoming

Earnings

11NovConfirmed

Q4 2022

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Next

-1.16

-0.27

0.63

1.52

Expected EPS

-0.375

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ABEO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Biogen focuses on developing therapies for neurological and neurodegenerative diseases, directly competing with Abeona's gene therapy approach for similar disorders.

Pfizer has a broad portfolio including gene therapies targeting rare diseases, overlapping with Abeona's focus areas.

Sangamo Therapeutics

Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing in the same space as Abeona for genetic disorders.

Biomarin Pharmaceutical

BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for rare diseases, directly competing with Abeona's rare disease focus.

bluebird bio focuses on gene therapies for genetic diseases and cancer, competing in the gene therapy space with Abeona.

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical targets rare and ultra-rare diseases with its drug development, similar to Abeona's focus.

Sarepta Therapeutics

Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics and gene therapy for rare diseases, competing with Abeona's gene therapy approach.

Vertex Pharmaceuticals

Vertex Pharmaceuticals engages in developing therapies for treating cystic fibrosis and other serious diseases, competing in the rare disease market with Abeona.

Novo Nordisk focuses on a broad range of treatments including for rare diseases, potentially competing with Abeona in the gene therapy and rare disease market.

Analyst Ratings

19$Average Price Target

The highest estimate is $21.

From 3 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

About

Health Technology

Pharmaceuticals: Generic

Manufacturing

Pharmaceutical Preparation Manufacturing

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Show more...

CEO

Joao Siffert

Employees

84

Country

US

ISIN

US00289Y1073

WKN

000A3DMHM

Listings